ProKidney Corp
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About PROK
ProKidney Corp. is a clinical-stage cellular therapeutics company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. It is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Find out what a historical investment in ProKidney Corp would be worth today using our PROK stock calculator.
$232.23M
-
0.00%
583.22K
$0.81
$0.75
$0.80
$4.35
$0.46
Ready to start your investing journey with Stake?
Open an accountPROK FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in PROK
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in PROK
on Stake
Buy PROK from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of PROK from only US$10 with fractional shares
